Milella M - Search Results

1

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.

Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Milella M, et al. Blood. 2002 May 1;99(9):3461-4. doi: 10.1182/blood.v99.9.3461. Blood. 2002. PMID: 11964319 Free article.

2

Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis.

Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Carter BZ, et al. Among authors: milella m. Blood. 2003 Dec 1;102(12):4179-86. doi: 10.1182/blood-2003-03-0960. Epub 2003 Aug 14. Blood. 2003. PMID: 12920030 Free article.

3

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.

Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. Milella M, et al. Blood. 2007 Mar 1;109(5):2121-9. doi: 10.1182/blood-2006-05-024679. Epub 2006 Oct 31. Blood. 2007. PMID: 17077328 Free article.

4

Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells.

Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Carter BZ, et al. Among authors: milella m. Cell Cycle. 2003 Sep-Oct;2(5):488-93. Cell Cycle. 2003. PMID: 12963850

5

The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.

Milella M, Kornblau SM, Andreeff M. Milella M, et al. Rev Clin Exp Hematol. 2003 Jun;7(2):160-90. Rev Clin Exp Hematol. 2003. PMID: 14763161 Review.

6

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.

Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A; GIMEMA Acute Leukemia Working Party. Gregorj C, et al. Among authors: milella m. Blood. 2007 Jun 15;109(12):5473-6. doi: 10.1182/blood-2006-05-021071. Epub 2007 Mar 9. Blood. 2007. PMID: 17351113 Free article.

7

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Ricciardi MR, et al. Among authors: milella m. J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8. J Mol Med (Berl). 2012. PMID: 22399013

8

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L. Milella M, et al. Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013. Sci Rep. 2017. PMID: 28220839 Free PMC article.

9

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A. Iacovelli S, et al. Among authors: milella m. Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156. Oncotarget. 2015. PMID: 26392332 Free PMC article.

10

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.

Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. Gatto S, et al. Among authors: milella m. Haematologica. 2003 Aug;88(8):853-63. Haematologica. 2003. PMID: 12935973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

636 results

Search Page